• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crinetics Pharmaceuticals Inc (NQ: CRNX )

    59.16 +1.35 (+2.34%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,042,424
    Open 60.02
    Bid (Size) 54.08 (1)
    Ask (Size) 88.00 (1)
    Prev. Close 57.81
    Today's Range 58.58 - 60.91
    52wk Range 25.75 - 60.91
    Shares Outstanding 54,026,103
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +67.17%
    +67.17%
    1 Month
    +14.30%
    +14.30%
    3 Month
    +22.48%
    +22.48%
    6 Month
    +16.25%
    +16.25%
    1 Year
    +100.41%
    +100.41%

    More News

    Read More
    Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    What Analysts Are Saying About Crinetics Pharmaceuticals Stock
    Via Benzinga
    A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
    Via Benzinga
    Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
    Via Benzinga
    17 Analysts Have This To Say About Crinetics Pharmaceuticals
    Via Benzinga
    Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    7 Biotech Stocks to Boost Your Portfolio to Peak Health
    Via InvestorPlace
    EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.